Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis

NCT07469891 is registered in ClinicalTrials.gov with Prelude Therapeutics Incorporated as lead sponsor.

NCT NCT07469891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07469891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis
Lead sponsor
Prelude Therapeutics Incorporated
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2026
Completion date
April 30, 2028
Enrollment
100 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf), myeloproliferative neoplasms (mpns), polycythemia vera (pv), post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis (pmf)